Breaking News Instant updates and real-time market news.

GPRO

GoPro

$16.74

0.06 (0.36%)

, OPK

OPKO Health

$10.69

0.1 (0.94%)

08:45
10/04/16
10/04
08:45
10/04/16
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: GoPro (GPRO) 80.32% +7.61, Opko Health (OPK) 8.29% +2.70, Himax Technologies (HIMX) 7.52% +1.56, Ctrip.com (CTRP) 1.50% +1.09, MannKind (MNKD) 19.88% +0.90, Novavax (NVAX) 11.06% +0.77, Sarepta (SRPT) 2.84% +0.35, Direxion Junior Gold (JNUG) 8.04% +0.33, ProShares Ultra VIX Short Term Futures (UVXY) 5.43% +0.28, and P&G (PG) 0.54% +0.28.

GPRO

GoPro

$16.74

0.06 (0.36%)

OPK

OPKO Health

$10.69

0.1 (0.94%)

HIMX

Himax

$8.67

0.08 (0.93%)

CTRP

Ctrip.com

$46.95

0.38 (0.82%)

MNKD

MannKind

$0.63

0.0086 (1.39%)

NVAX

Novavax

SRPT

Sarepta

$60.95

-0.46 (-0.75%)

PG

Procter & Gamble

$88.66

-1.09 (-1.21%)

  • 11

    Oct

  • 11

    Oct

  • 25

    Oct

  • 06

    Nov

  • 12

    Dec

GPRO GoPro
$16.74

0.06 (0.36%)

09/28/16
BOFA
09/28/16
NO CHANGE
BOFA
New drone competitor won't knock down GoPro Karma, says BofA/Merrill
After DJI announced its Mavic drone, BofA/Merrill analyst Jason Mitchell says that the product will appeal more to drone enthusiasts, while GoPro's Karma drone will be more popular with casual consumers and those focused on film. The analyst sees "little risk" to his Q4 estimates for GoPro as a result of Mavic's launch ,since he did not expect GoPro to obtain much revenue from Karma in Q4. Although the analyst believes that Mavic increases GoPro's risk in fiscal 2017, he continues to believe that Karma will be able to obtain a 4%-5% share of the drone market in fiscal 2017. Mitchell keeps a $19 price target and Buy rating on GoPro.
09/28/16
OPCO
09/28/16
NO CHANGE
OPCO
DJI Mavic Pro not a response to GoPro Karma, says Oppenheimer
After drone market leader DJI unveiled its Mavic Pro, Oppenheimer analyst Andrew Uerkwitz notes that he does not see it as a response to GoPro's Karma, arguing that they have two very different value propositions. Mavic is a high-performance, versatile consumer drone that pushes boundaries of the category to new heights, while Karma is a well-rounded and versatile flying camera system, he contended. Nonetheless, Uerkwitz believes GoPro's brand and customer loyalty will be tested given an acceleration in innovation and several compelling drones introduced this year across the market.
09/20/16
OPCO
09/20/16
NO CHANGE
OPCO
Perform
GoPro executing on focused strategy, says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz notes that GoPro has unveiled upgraded cameras, a drone, a hand-held gimbal, and more user-friendly software and services. The analyst believes these upgrades play to GoPro's strengths and will appeal to core users. Further, Uerkwitz says the company keeps executing on a focused strategy that results in what he sees as the "strongest" product portfolio to date. Nonetheless, the analyst points out that concerns over the structural decline of its addressable market keep him on the sideline, reiterating a Perform rating on the shares.
09/20/16
09/20/16
NO CHANGE

Stifel still skeptical on new GoPro product line
Stifel analyst Jim Duffy remains skeptical about the ability of GoPro's new Hero5 products to restore enthusiasm in the company's offerings. The analyst says that the company's failure to incorporate "follow me" mode into its new Karma drone and the drone's high price tag are negative. The analyst thinks that Street forecasts of 20% revenue compound annual growth from 2016-2018 "appear aggressive." He keeps a Hold rating on the shares.
OPK OPKO Health
$10.69

0.1 (0.94%)

03/30/16
LTCO
03/30/16
NO CHANGE
Target $20
LTCO
Buy
OPKO Health should be bought on any weakness, says Ladenburg
Ladenburg analyst Kevin DeGeeter encourages investors to use any weakness in OPKO Health's stock price as an "attractive opportunity" to accumulate shares. The company received a Complete Response Letter from FDA due to third party manufacturing issues for oral Rayaldee at 30mcg daily in the treatment of secondary hyperparathyroidism, but the analyst does not expect it to have a "material impact" on his projected Q3 Rayaldee launch. DeGeeter reiterates his Buy rating and $20 price target on the shares.
06/03/16
STPT
06/03/16
INITIATION
Target $16
STPT
Buy
OPKO Health initiated with a Buy at Standpoint Research
Target $16.
04/27/16
LTCO
04/27/16
NO CHANGE
Target $20
LTCO
Buy
OPKO Health resubmission of Rayaldee lifts overhang, says Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter believes OPKO Health resubmission of the New Drug Application for Rayaldee, which he notes came roughly within the timeframe he expected, lifts a potential overhang on the stock. The acceptance of the resubmission and issuance of a new PDUFA date suggest the issues identified by FDA at the third party supplier was limited and a suitable plan has been communicated, DeGeeter tells investors. The analyst keeps a Buy rating and $20 price target on OPKO shares.
03/31/16
JEFF
03/31/16
NO CHANGE
Target $11
JEFF
Hold
Uncertainty may persist after Opko's Health drug setback, says Jefferies
Jefferies analyst Brandon Couillard says the FDA's complete response letter to Opko's Health's New Drug Application for Rayaldee as a treatment for secondary hyperparathyroidism was a surprise. While nonfatal, the analyst believes the setback adds a new level of uncertainty around a key value driver that could weigh on the stock well into the second half of 2016. Couillard has a Hold rating and $11 price target on the shares.
HIMX Himax
$8.67

0.08 (0.93%)

09/26/16
NOMU
09/26/16
DOWNGRADE
NOMU
Neutral
Himax downgraded to Neutral from Buy at Nomura
09/28/16
ROTH
09/28/16
INITIATION
Target $10
ROTH
Buy
Himax initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Himax with a Buy and a $10 price target. Desilva believes newer HIMX products can participate in growth of IoT device categories such as augmented reality and virtual reality head-mounted devices.
09/29/16
FBCO
09/29/16
NO CHANGE
FBCO
Outperform
Himax long-term story intact, says Credit Suisse
Credit Suisse analyst Jerry Su lowered Himax's LCOS/WLO shipment assumptions for Q4-1H 2017 on slower new platform adoption following supply chain checks. Su said the 2018 AR device ramp is on track and believes Himax's long-term story on consumer AR glass and 3D sensing for smartphone remains intact, since the capacity ramp up remains on schedule. The analyst said the potential launch of consumer AR glass and 3D sensing for smartphone should boost Himax's earnings in 2018 and reiterates his Outperform rating and $14 price target.
09/02/16
NOMU
09/02/16
NO CHANGE
Target $12
NOMU
Buy
Himax price target raised to $12 on better pricing at Nomura
Nomura analyst Donnie Teng noted that Himax has been able to raise its prices for its liquid crystal on silicon, or LCOS, and wafer level optics, or WLO, for a major augmented reality device recently, which he believes could help the company reach the higher end of its Q3 sales guidance. Teng raised his price target on Himax shares to $12 from $9.70, adding that the company plans to try to provide more cost effective LCOS and WLO products for a possible consumer AR device in 2018, which lead to higher demand. Nomura keeps a Buy rating on the stock.
CTRP Ctrip.com
$46.95

0.38 (0.82%)

08/31/16
JPMS
08/31/16
INITIATION
Target $53
JPMS
Overweight
Ctrip.com assumed with an Overweight at JPMorgan
JPMorgan analyst Alex Yao assumed coverage of Ctrip.com with an Overweight rating and raised his price target for the shares to $53 from $47. The rating is unchanged from the firm's prior coverage.
09/01/16
STFL
09/01/16
NO CHANGE
STFL
Ctrip.com price target raised to $56 from $52 at Stifel
Stifel analyst George Askew says that Ctrip.com reported "strong" results and provided "solid" revenue guidance. The analyst remains upbeat on the company's fundamentals and expects its EBITDA margins to be close to 30% in coming years. He keeps a Buy rating on the shares.
08/17/16
OPCO
08/17/16
NO CHANGE
Target $55
OPCO
Outperform
Ctrip.com should be bought on any near-term weakness, says Oppenheimer
Oppenheimer analyst Jed Kelly believes Ctrip.com (CTRP) will likely beat Wall Street's Q2 revenue and margin estimates given a stable travel environment. However, the analyst says that increasing competition, and Qunar's (QUNR) ongoing China Southern dispute, could produce cautious commentary around Q3 profit and cause volatility in the shares. Nonetheless, Kelly sees Ctrip.com as well positioned to gain share of China's under-penetrated online travel market, and would take advantage of any near-term weakness to accumulate shares. He reiterates an Outperform rating and $55 price target on Ctrip.com's shares.
06/16/16
BMUR
06/16/16
NO CHANGE
Target $52
BMUR
Buy
Ctrip.com price target lowered to $52 from $56 at Brean Capital
Brean Capital lowered its price target on Ctrip.com (CTRP) to $52 from $56 after the company posted solid results, but provided soft guidance, which was mainly attributed to the near-term revenue growth pressure from Qunar (QUNR) given the recent adjustment of the air ticketing business and the changes to Qunar's hotel business targeting profitable growth. Brean Capital views Ctrip.com as a core holding and reiterated its Buy rating on its shares.
MNKD MannKind
$0.63

0.0086 (1.39%)

03/15/16
PIPR
03/15/16
NO CHANGE
Target $0.05
PIPR
Underweight
MannKind has 'very short window' to turn launch around, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer attributes MannKind's (MNKD) greater than expected Q4 loss to non-cash impairment charges related to the termination of its commercial agreement with Sanofi (SNY) for Afrezza. The company has a "very short window within which to sufficiently inflect the launch" given its limited financial resources, Schimmer tells investors in a post-earnings research note. He reiterates an Underweight rating on MannKind shares with a 5c price target.
05/10/16
PIPR
05/10/16
NO CHANGE
Target $10
PIPR
Underweight
Piper doubles MannKind price target to 10c from 5c
To reflect MannKind's ability to raise capital "at valuations far above what we would have expected," Piper Jaffray analyst Joshua Schimmer doubled his price target for the shares to 10c from 5c. The stock is trading down 20c to $1.12 in the pre-market after MannKind reported Q1 results and announced a 48.54M share registered direct public offering that priced at $1.03 per share. The financing seems to extend the company's cash runway through early 2017, Schimmer tells investors in a research note. The analyst still struggles to see how MannKind's "cash-strapped launch plans" can drive meaningful adoption of Afrezza in a difficult insulin market. He reiterates an Underweight rating on MannKind.
08/09/16
PIPR
08/09/16
NO CHANGE
Target $0.1
PIPR
Underweight
MannKind cash strapped, Afrezza sales 'abysmal,' says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer reiterates an Underweight rating on shares of MannKind with a 10c price target following the company's Q2 results. "Cash strapped" MannKind will have a tough time inflecting "rather abysmal" Afrezza sales rapidly enough to offset its cash burn, Schimmer tells investors in a post-earnings research note.
02/04/16
PIPR
02/04/16
NO CHANGE
Target $0.05
PIPR
Underweight
Piper calls MannKind a penny stock with a mid-cap valuation
Piper Jaffray analyst Joshua Schimmer calls MannKind's business strategy "flawed and desperate" following the company's conference call yesterday to discuss recent developments. The company is trying to appeal to "less sophisticated retail investors," Schimmer tells investors in a research note. MannKind does not have the ability to generate adequate revenue to offset the spending requirements over the next 12 months for Afrezza, the analyst contends. Schimmer sees no reason to own the shares and believes the likelihood that the company declares bankruptcy this year "is not out of the realm of possibility." He calls MannKind a "penny stock company with a mid-cap valuation." The analyst reiterates an Underweight rating on the biopharmaceutical company with a 5c price target. The stock closed yesterday down 1c to 99c.
NVAX Novavax

09/16/16
WEDB
09/16/16
DOWNGRADE
Target $2
WEDB
Neutral
Novavax downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Heather Behanna downgraded Novavax to Neutral and lowered its price target to $2 from $14 after the company's Phase III trial of RSV vaccine failed. This is the fourth downgrade of Novavax today.
09/16/16
LTCO
09/16/16
DOWNGRADE
LTCO
Neutral
Novavax downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Novavax to Neutral without a price target after the company's Phase III trial for the RSV F nanoparticle vaccine failed. Shares were also downgraded this morning at Piper Jaffray and JPMorgan.
09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
SBSH
09/16/16
DOWNGRADE
Target $1.5
SBSH
Neutral
Novavax downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Novavax to Neutral after the company's RSV vaccine for older adults failed in Phase 3. The analyst does not expect results from the one remaining clinical trial until 2019. He cut his price target for the shares to $1.50 from $12. Four other firms downgraded Novavax this morning.
SRPT Sarepta
$60.95

-0.46 (-0.75%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $64
PIPR
Overweight
Sarepta stock issuance strengthens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics has a strengthened balance sheet after issuing 5.02M shares at a price of $59.75. Further, for its Exondys51 approval, Sarepta gained a Rare Priority Review Voucher that could be sold to further pad the company's cash position, Tenthoff tells investors in an intraday research note. He reiterates an Overweight rating on the shares with a $64 price target. The stock is down 5% to $57.74 in late afternoon trading.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
PG Procter & Gamble
$88.66

-1.09 (-1.21%)

08/26/16
JEFF
08/26/16
NO CHANGE
Target $75
JEFF
Hold
Jefferies cuts Edgewell Personal Care target citing Harry's rollout at Target
Jefferies analyst Kevin Grundy lowered his price target on Edgewell Personal Care (EPC) to $75 from $77 after Harry's shave club offerings launched nationwide at Target (TGT), saying his store checks revealed strong in-store execution for the roll-out. Grundy thinks soon-to-be acquired Dollar Shave Club will also to push into retail and expects other retailers, perhaps including Walmart (WMT), to follow Target's lead and offer shelf space to the "trendy" shave club brands. While saying this is also a risk to Procter & Gamble (PG), Grundy keeps his Buy rating and $98 price target on P&G shares, saying increased levels of investment in U.S. shaving are already factored in the company's guidance.
08/15/16
08/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) upgraded to Buy from Neutral at B. Riley with analyst Linda Bolton Weiser saying she left a meeting with new Chief Executive Officer David Taylor with greater confidence in the company's improved organic sales growth. 2. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho. 3. AAC Holdings (AAC) upgraded to Strong Buy from Outperform at Raymond James with analyst John Ransom ting favorable valuation, still high short interest, and good visibility on 2017 EBITDA, which is $8M above Street estimates. 4. American Eagle (AEO) upgraded to Buy from Hold at Deutsche Bank with analyst Tiffany Kanaga saying denim strength should drive upside to estimates in the second quarter while easier compares should keep the momentum going in the second half of 2016. 5. Bright Horizons (BFAM) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Steinerman saying the company is entering a period of above-average margin expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/16
RILY
08/15/16
UPGRADE
Target $105
RILY
Buy
Procter & Gamble upgraded to Buy from Neutral at B. Riley
B. Riley analyst Linda Bolton Weiser upgraded Procter & Gamble to Buy saying she left a meeting with new CEO David Taylor with greater confidence in the company's improved organic sales growth. The analyst expects Procter & Gamble's multiple to continue expanding and she upped her price target for the shares to $105 from $74.
07/22/16
STFL
07/22/16
NO CHANGE
STFL
Procter & Gamble price target raised to $92 from $85 at Stifel
Stifel expects Procter & Gamble's stock to be boosted by multiple expansion, driven by improving organic sales in fiscal 2017. The firm says that the company's margins should continue to expand. It believes that the stock's valuation is attractive, and it keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDEX

PRO-DEX

$4.48

0.034 (0.76%)

17:06
12/09/16
12/09
17:06
12/09/16
17:06
Syndicate
Breaking Syndicate news story on PRO-DEX »

PRO-DEX files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBX

Peoples Financial

$14.50

-0.5 (-3.33%)

17:02
12/09/16
12/09
17:02
12/09/16
17:02
Hot Stocks
Breaking Hot Stocks news story on Peoples Financial »

Jeffrey L. Gendell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUIK

QuickLogic

$0.94

-0.0163 (-1.71%)

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Syndicate
Breaking Syndicate news story on QuickLogic »

QuickLogic files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRZA

Starz

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Hot Stocks
Breaking Hot Stocks news story on Starz »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Syndicate
Breaking Syndicate news story on Belmond »

Belmond files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Hot Stocks
Breaking Hot Stocks news story on Parnell »

Parnell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, SHAK

Shake Shack

$38.08

0.82 (2.20%)

16:50
12/09/16
12/09
16:50
12/09/16
16:50
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Shake Shack »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

SHAK

Shake Shack

$38.08

0.82 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, LXFT

Luxoft

$54.40

-1.8 (-3.20%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Luxoft »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

LXFT

Luxoft

$54.40

-1.8 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
H.B. Fuller announces restructuring plan »

On December 7, H.B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDXS

Codexis

$4.95

-0.1 (-1.98%)

16:38
12/09/16
12/09
16:38
12/09/16
16:38
Syndicate
Breaking Syndicate news story on Codexis »

Codexis files $80M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$156.49

1.1 (0.71%)

, AMZN

Amazon.com

$768.66

1.33 (0.17%)

16:35
12/09/16
12/09
16:35
12/09/16
16:35
General news
On The Fly: Stocks end week at record highs ahead of Fed meeting »

The Dow, the Nasdaq and…

BA

Boeing

$156.49

1.1 (0.71%)

AMZN

Amazon.com

$768.66

1.33 (0.17%)

UA

Under Armour

$28.81

-0.01 (-0.03%)

SFTBF

SoftBank

$68.31

-0.532 (-0.77%)

S

Sprint

$8.48

-0.26 (-2.97%)

TMUS

T-Mobile

$56.74

-1.81 (-3.09%)

JNJ

Johnson & Johnson

$112.26

1.27 (1.14%)

MRK

Merck

$61.23

1.11 (1.85%)

LLY

Eli Lilly

$67.85

0.66 (0.98%)

NVS

Novartis

$69.74

2.15 (3.18%)

PFE

Pfizer

$31.70

0.76 (2.46%)

CELG

Celgene

$113.39

0.33 (0.29%)

BIIB

Biogen

$287.75

-1.79 (-0.62%)

AMGN

Amgen

$143.45

2.86 (2.03%)

MYL

Mylan

$36.51

0.45 (1.25%)

ESRX

Express Scripts

$72.48

1.73 (2.45%)

KO

Coca-Cola

$42.00

1.02 (2.49%)

CNSL

Consolidated Communications

$27.38

-0.25 (-0.90%)

FRP

FairPoint

$19.05

-0.2 (-1.04%)

VZ

Verizon

$51.49

0.36 (0.70%)

EQIX

Equinix

$346.03

-0.43 (-0.12%)

ROP

Roper Technologies

$185.80

2.51 (1.37%)

SNCR

Synchronoss

$41.21

0.42 (1.03%)

IL

Intralinks

$13.09

0.04 (0.31%)

ABT

Abbott

$39.20

0.52 (1.34%)

ALR

Alere

$37.58

0.23 (0.62%)

SKYAY

Sky

$49.95

10.29 (25.95%)

FOX

21st Century Fox

$27.92

-0.56 (-1.97%)

FOXA

21st Century Fox

$28.21

-0.43 (-1.50%)

SWC

Stillwater Mining

$17.32

2.64 (17.98%)

SBGL

Sibanye Gold

$7.10

-1.26 (-15.07%)

BOBE

Bob Evans

$54.64

-0.13 (-0.24%)

FRAN

Francesca's

$21.19

-1.07 (-4.81%)

PLAY

Dave & Buster's

$57.18

0.56 (0.99%)

LULU

lululemon

$69.30

0.46 (0.67%)

TLRD

Tailored Brands

$27.18

0.92 (3.50%)

COST

Costco

$159.70

2.11 (1.34%)

AVGO

Broadcom

$179.09

8.38 (4.91%)

MIK

Michaels

$23.53

-0.23 (-0.97%)

VRA

Vera Bradley

$12.95

0.13 (1.01%)

OXM

Oxford Industries

$62.74

0.33 (0.53%)

SHLD

Sears

$11.93

-0.83 (-6.50%)

HRB

H&R Block

$22.95

0.16 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 15

    Dec

  • 15

    Dec

  • 04

    Jan

  • 09

    Jan

  • 09

    Jan

  • 24

    Jan

  • 08

    Mar

  • 28

    Mar

  • 19

    Jul

DYN

Dynegy

$8.98

0.77 (9.38%)

16:34
12/09/16
12/09
16:34
12/09/16
16:34
Hot Stocks
Dynegy, Genco receive votes in favor of Genco plan of reorganization »

Dynegy and Illinois Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.